Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the seven analysts that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 […]
Mersana Therapeutics (NASDAQ:MRSN) Upgraded at JPMorgan Chase & Co. themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) was upgraded by equities researchers at Truist Financial from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, Benzinga reports. The firm presently has a $9.00 price objective on the stock. Truist Financial’s price target would indicate a potential upside of 85.57% […]
Mersana Therapeutics (NASDAQ:MRSN) Issues Quarterly Earnings Results theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Nuvalent (NASDAQ:NUVL) Issues Earnings Results, Misses Estimates By $0.02 EPS themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.